as stem cell transplantation is an initial step in cost containment. We analyzed hospital charges for pediatric hematopoiKeywords: bone marrow transplantation/economics; etic stem cell transplantation (HSCT) to understand costs and cost analysis; economics; pediatrics better the medical origin of these charges. Forty-nine patients undergoing HSCT at Kosair Children's Hospital between January 1992 and August 1995 had hospital charges analyzed by cost center, donor type and clinical Health care costs are an increasingly important consideroutcome. Thirty-three autologous, two syngeneic and 14 ation in health care delivery. In the USA, federal and state allogeneic transplants were performed. Twenty-four governments, as well as business have encouraged a trantransplants were performed for hematological maligsition to a 'business model of medicine' resulting in a pronancies, 22 for solid tumors, and three for non-maligliferation of for-profit managed care corporations that seek nant diseases. Pharmaceutical charges comprised the to contain costs by applying competitive pressures to health largest single component of total hospital charges care providers. In Europe and Canada, rising health care (THC), accounting for 38.9%. Room charges were the costs are increasingly being constrained by shrinking next largest group at 33.7% of THC. Other cost centers, government budgets. in order of magnitude, were central supply (7.9%),
greater understanding of the costs of HSCT, which may transplants (TCD). The 33 autologous transplants included three which were purged with 4-hydroperoxycyclophosidentify cost efficiencies without sacrificing quality of care.
phamide for acute myelogenous leukemia (AML), one which was purged with vincristine, VP16 and verampamil for neuroblastoma, and two which were antibody-purged Patients and methods for neuroblastoma. Two of the 33 transplants were performed using peripheral stem cells.
Patients
The median age of patients was 10.6 years (range: 0.66-Forty-nine HSCT in 46 patients were included in this analy-22.2 years) with a male to female ratio of 1.5:1 (29 sis with patient characteristics described in Table 1 . One males/20 females). Three of the patients had non-malignant patient who died on day +2 was censored from this analyconditions (one each of Hurler's syndrome, aplastic anemia, sis. Seven patients (14%) died of transplant-related toxicity and Diamond-Blackfan anemia). Forty-six patients had prior to day 100. There were 33 autologous transplants, two malignant conditions: 24 with hematological malignancies syngeneic transplants (both on the same patient), and 14 and 22 with solid tumors. The hematological malignancies allogeneic transplants. The 14 allogeneic transplants included one chronic myelogenous leukemia in chronic included seven HLA-identical matched related donor transphase, one high risk acute lymphoblastic leukemia (ALL) plants (MRD), five matched unrelated donor transplants in first remission, eight ALLs in second remission or (MUD), and two related haploidentical T cell-depleted greater, six AMLs in first remission, three AMLs in second remission or greater, and five non-Hodgkin lymphomas in for total body irradiation (TBI) were included under pharmacy charges in the chemotherapy section so as to remove any bias in the cost analysis between patients receiving TBI plants for purposes of analysis. Charges were analyzed as stated and do not reflect actual revenue received. In in comparison to those receiving chemotherapy-only regimens. Physician charges are not included in this cost analyaddition, charges were not corrected for inflation during the 3. year period of analysis. sis, nor are charges for any pre-transplant evaluations conducted prior to admission for transplant, or charges related to treatment after initial hospital discharge. Charges related to acquisition of stem cells (eg bone marrow harvest, pheresis, MUD donor charges) are also not included in this Results analysis.
The mean total hospital charge (THC) for the 49 stem cell Supportive care transplants analyzed was $243 550 ± 15 575. THC were divided into generally recognized categories for purposes of All children were treated using standard HSCT supportive care algorithms and the best judgment of the attending analysis ( Figure 1 ). Pharmacy charges composed the largest single category of charges, accounting for mean charges of physician. The supportive care included surveillance cultures and full sterile isolation (sterile gowns, gloves and $91 822 ± 4814 or 38.9 ± 0.90% of THC. The second largest category of charges were room charges which accounted masks) for approximately two thirds of the time of study. Most blood products transfused were CMV-negative and all for $79 856 ± 4930 or 33.7 ± 0.90% of THC. No other single category accounted for more than 10% of THC. Other products were irradiated and leukocyte-depleted. Apheresis platelets were provided whenever possible, rather than rancategories were, in order of magnitude: central supply services ($19 600 ± 1667; 7.9 ± 0.39%); transfusion services dom donor units, and were transfused when the platelet count fell below 20 000/l. Hemoglobin was maintained ($18 270 ± 2260; 7.5 ± 0.50%); laboratory ($15 713 ± 2214; 5.8 ± 0.37%); microbiology ($8821 ± 734; 3.6 ± 0.21%); above 7 g/dl. Anti-emetic medications generally consisted of serotonin antagonists beginning in late 1992 (when they miscellaneous charges ($5950 ± 1620; 1.9 ± 0.33%) and radiology ($3517 ± 400; 1.4 ± 0.11%). Administration costs were first generally available in the USA), and standard cocktails of metoclopromide, anti-histamines and phenothifor i.v. fluids and medications, as well as i.v. tubing sets accounted for 37% of central supply charges. azines prior to that time. Colony-stimulating factors (G-and GM-CSF) were initiated on day +1 and discontinued when
There was a positive correlation between THC and the length of stay (LOS). For all patients, the correlation coefthe ANC exceeded 5000/l for 2 consecutive days. Patients received oral vancomycin and gentamicin for intestinal ficient between THC and LOS was 0.86. When patients were analyzed by donor type, the correlation between THC decontamination, fluconazole for fungal prophylaxis and were started on broad spectrum antibiotics if febrile and and LOS was 0.92 for autologous transplant patients and 0.70 for allogeneic patients. Linear regression analysis of neutropenic. Antibiotics, once started, were continued until the patients were afebrile with a sustained ANC greater charges for these patients showed a trend towards allogeneic patients generating greater daily hospital charges than 500/l. Amphotericin was initiated if the patients remained febrile in spite of broad spectrum antibiotics for than autologous patients ($7043 per day for allogeneic patients vs $5426 for autologous patients; P = 0.28). When greater than 5 to 7 days. All patients received intravenous immunoglobulin (IVIG) at a dose of 500 mg/kg/week. TPN ICU patients were excluded from the analysis, the correlation coefficient was 0.94 for non-ICU autologous patients was initiated and stopped at the discretion of the attending physician and incorporated variables such as the patient's and 0.65 for non-ICU allogeneic patients. There was a trend for non-ICU allogeneic patients to cost less per day than pre-transplant nutritional status and current oral intake.
To be discharged from the inpatient unit, patients had to non-ICU autologous patients, with allogeneic patients generating $3493 in THC per day vs $5145 for non-ICU autobe afebrile on no antibiotics, require transfusion support no more frequently than every third day, and be able to mainlogous patients (P = 0.17). When patients were analyzed by complexity of care, regardless of donor type, the correlation tain an ANC greater than 500/l with or without colonystimulating factor support. Patients generally had to be able between THC and LOS was 0.83 for patients who were transferred to the ICU during their admission and 0.91 for to take sufficient sustenance to maintain weight and hydration, although in rare instances, patients were sent patients who did not require ICU transfer. As might be expected, there was a significant difference in charges home with TPN.
between these two patient groups with ICU patients generating $8474 per day in THC compared to $4947 per day Statistical analysis and inflation adjustment for non-ICU patients (P = 0.01). There was no significant difference in daily hospital charges when autologous and Statistical analysis was by a two-tailed t test as indicated. Fisher's exact test was calculated using StatXact3 (Cytel allogeneic ICU patients were analyzed separately ($10 398 per day for allogeneic ICU patients vs $6753 per day for software, Cambridge, MA, USA). Linear regression analysis, the Mann-Whitney U test and the partial F statistic autologous ICU patients (P = 0.50). The relatively small number of patients in this group however (n = 8), may have (for calculating the significance of the difference between regression lines) were calculated using SPSS (SPSS Inc, included the statistical power of this comparison. The correlation coefficient between THC and LOS for these two Chicago, IL, USA). Correlation coefficients were calculated using Excel 97 (Microsoft, Redmond, WA, USA). The two patient groups was 0.81 for autologous ICU patients and 0.90 for allogeneic ICU patients. syngeneic transplants were included with autologous trans- . Anti-emetics charges were further divided into subcategories that were $8815 ± 936 (10.0 ± 1.25% of TPC; 4.1 ± 0.56% of included antibiotics (including anti-virals and those used THC). Conditioning therapy was $7875 ± 653 (9.8 ± 0.87% for prophylaxis), colony-stimulating factors, TPN, IVIG, of TPC; 3.9 ± 0.41% of THC). Finally, IVIG accounted for anti-emetics and chemotherapy ( Figure 2 ). Colony-stimul-$3382 ± 321 (3.2 ± 0.35% of TPC; 1.3 ± 0.15% of THC). ating factors accounted for the largest single pharmacy cateTaken together, these six groups of pharmaceuticals gory, accounting for $18 024 ± 1790 in charges. This was accounted for $61 558 ± 3310 in charges, 68.3 ± 1.65% of 17.9 ± 1.1% of total pharmacy charges (TPC) and TPC and 26.9 ± 1.04% of THC. 7.1 ± 0.49% of THC. Antibiotics were the next largest cate- comparisons were made between allogeneic and autologous patients for drug categories individually tracked (eg antibiotics, anti-emetics, chemotherapy, colony-stimulating The probability of an allogeneic patient being transferred factors, IVIG and TPN), all except antibiotics accounted to the ICU was 36% (five out of 14), while it was only 9% for less in both absolute (eg total dollars) and relative (eg for autologous and syngeneic patients (three out of 35; P percent of THC) charges in allogeneic patients than in auto-Ͻ 0.03 by Fisher's exact test). The mean THC for an allogeneic transplant patient transferred to the ICU was logous patients (Table 2 ). Since TPC were higher in allo- geneic patients, this suggests that other non-tracked drugs compared to 34.4 ± 0.99% for non-ICU patients (P = 0.34). This seemingly contradictory result was accounted for by were more significant in allogeneic patients than in autologous patients. This observation was reinforced by the findthe increased intensity of care reflected in a variety of other cost centers. Cost centers making up a greater percentage ing that the tracked drugs as a group constituted 71.6 ± 1.74% of TPC in the autologous group, but only of THC in ICU patients than in non-ICU patients were the laboratory and radiology groupings, as well as the miscel-60.5 ± 3.08% in the allogeneic group (P Ͻ 0.005). Similarly, these drugs as a group constituted 28.7 ± 1.22% of laneous cost center. The miscellaneous cost category included charges for ventilator management, as well as THC in the autologous group, but only 22.3 ± 1.61% in the allogeneic group (P Ͻ 0.01).
charges for specialized renal, endoscopic, pulmonary, neurologic and cardiac function tests and support that as Comparisons of charges between autologous and allogeneic transplants were made for other categories as well expected, were more extensively used in critically ill patients. Transfusion service charges as a percentage of ( Table 3 ). The laboratory and supply cost centers were of greater relative magnitude (percentage of total charges) in THC were not statistically different in ICU patients as compared to non-ICU patients and pharmacy charges constiallogeneic transplant patients. No cost centers were of statistically significant lesser relative magnitude. Room tuted a smaller percentage of THC in ICU patients than in non-ICU patients. In addition, the individually tracked charges were statistically similar in both absolute and relative terms, accounting for charges of $84 786 ± 8553 in pharmacy items made up a smaller percentage of both TPC (ICU: 57.0 ± 4.49% vs non-ICU, 71.2 ± 1.58%; ratio: 0.80; autologous patients (33.9 ± 1.20% of THC) and $96 209 ± 8883 in allogeneic patients (33.1 ± 1.18%).
P Ͻ 0.005) and THC (ICU: 19.8 ± 2.59% vs non-ICU, 28.5 ± 1.03%; ratio: 0.70; P Ͻ 0.005) in ICU patients as compared to non-ICU patients. Both these observations pre-
Complexity of clinical course and outcome
sumably reflect the extensive use of a wider variety of drugs and other supportive care measures in ICU patients than in Eight patients were transferred to the ICU during their transplant course. Five of these were allogeneic transplant non-ICU patients.
Five of the eight patients transferred to the ICU died of patients and three were autologous transplant patients. Total hospital charges for ICU patients were $367 634 ± 49 135 transplant-related toxicity prior to day 100. In addition, two other patients not admitted to the ICU during their transcompared to $219 359 ± 13 779 for those not requiring transfer (P Ͻ 0.001). Median length of stay for ICU plant course also died of toxicity prior to day 100. THC for patients succumbing to transplant-related toxicity prior patients was 53 days as compared to 37 for patients not transferred to the ICU (P = 0.026 using the Mann-Whitney to day 100 were $400 751 ± 46 048. In contrast, THC for all other patients were $218 403 ± 12 190 (P Ͻ 0.025). U test). Room charges were 1.43 times greater for ICU patients than non-ICU patients (Table 4 ). In spite of the increased absolute room charge for ICU patients, the percentage of THC was only 29.9 ± 1.81% for ICU patients Discussion
Increasing importance has been placed on medical care ventional treatment, [3] [4] [5] and with or without the use of colony-stimulating factors. [10] [11] [12] [13] [14] The only other analysis to may reflect greater variability in the clinical courses of both the allogeneic and ICU transplant groups. There was a trend incurred during HSCT. It is hoped this analysis will allow estimates of the financial impact of various clinical changes for greater daily THC in allogeneic patients than autologous patients. Curiously, this trend reversed when ICU patients in the care of HSCT patients. For example, costs for colony-stimulating factors made up the largest single compowere excluded from the analysis. Thus it appears that taken as a group, allogeneic patients consume hospital resources nent of pharmacy charges (18%) and 7% of THC. In our HSCT program, as in many others, colony-stimulating facat a greater daily rate than autologous patients, but that this can be attributed to their more frequent utilization of the tors are begun on the first day post-transplant. There is some preliminary evidence, however, that colony-stimulat-ICU than autologous transplant patients. In addition, these data indicate that allogeneic patients generate higher hospiing factors may be initiated later in the transplant course without any delay in marrow recovery. 22, 23 Our data may tal charges on a daily basis than autologous patients and that their greater THC are not simply a reflection of a subsequently encourage some programs to delay the initiation of colony-stimulating factors. Caution must be longer LOS. This is consistent with the findings that allogeneic patients utilized significantly more resources in the used in this decision, since an additional 1 or 2 days of hospitalization may eliminate any potential savings. Similaboratory and supply categories than autologous patients did.
larly, studies have shown that for adequately nourished patients, TPN provides no survival advantage nor accelerPharmacy charges composed the largest single group of hospital charges, making up 39% of THC. Sixty-eight peration of hematopoietic reconstitution. 24, 25 In spite of these findings, however, many transplant programs routinely procent of pharmacy charges and 27% of THC could be attributed to colony-stimulating factors, antibiotics, TPN, vide TPN support to all patients, regardless of need. Since charges for TPN account for 11% of all pharmacy charges chemotherapy, anti-emetics and IVIG. The two largest drug categories, colony-stimulating factors and antibiotics made and 4% of THC, more judicious use of TPN may provide significant savings without compromising patient care. up 34% of TPC and 13% of THC. Room charges composed the next largest cost category, making up 34% of THC.
Analogous arguments have been made regarding the dual use of CMV screening and leukocyte depletion filters for Not surprisingly, patients transferred to the ICU had room charges that were 43% greater than non-ICU patients.
blood product transfusions. 20 The addition of more effective platelet pheresis leukodepletion systems serves as yet Finally, transfusion service charges were analyzed in detail as well. Surprisingly, platelet acquisition charges accounted another modality where cost and effectiveness need to be considered. for nearly half the total cost of all transfusion services. We attribute this finding to significant costs associated with Within our own institution, we have made changes based on these findings. Intravenous tubing costs accounted for providing single donor platelet pheresis products to our patients, rather than random donor units.
nearly 3% of THC (37% of supply costs, which were 7.9% of THC). Nursing policy during this period was to replace We also compared patient charges based on donor type (ie allogeneic vs autologous) and the complexity of the i.v. tubing daily. We have recently adopted a policy of tubing changes every 3 days without any change in the incitransplant course based on whether transfer to the ICU was necessary and if the patient survived to day 100 post-transdence of infection. Similarly, for well-nourished patients we have decreased our use of TPN, again without any plant. Not surprisingly, there was considerable overlap between patients undergoing more complex transplants (eg change in outcome. We have also modified our isolation procedures, and in keeping with recent studies, no longer allogeneic) and patients requiring transfer to the ICU and/or not surviving to day 100. Allogeneic transplant patients perform surveillance cultures 26 or use full sterile isolation. 27 Instead, we use a modified form of isolation with HEPAwere four times more likely to be transferred to the ICU than autologous patients (36 vs 9%). When all allogeneic filtered rooms, masks and gowns with good handwashing techniques. Finally, in accordance with the results of recent patients were compared with all autologous patients, the total costs of allogeneic transplants were 35% greater than studies, 28, 29 we have eliminated the use of IVIG for autologous transplant patients, and are considering its elimination autologous transplants. If ICU patients were excluded from this analysis, then the cost was only 18% greater. When for allogeneic patients as well. The current analysis reflects hospital charges rather than allogeneic and autologous ICU patients were compared, this difference was 21%.
actual costs or reimbursement. Hospital data on actual costs and reimbursement were unavailable for analysis. Detailed Patients transferred to the ICU during their hospital course had THC 68% greater than those not requiring transreview of the 'cost' literature in the area of HSCT, however, demonstrates that this limitation has also affected fer. This increased intensity of care was reflected in a greater proportion of charges attributed to laboratory tests, many previous studies, 10, 12, 14, 16, 17, 21 especially those in the USA where a non-governmental third party payer system radiological tests, and miscellaneous services. Miscellaneous charges reflected adjuncts to care often associated introduces distortions between charges and costs. Moreover, because of the increasingly competitive health care with ICU patients such as ventilator management, echocardiography, endoscopy and renal dialysis. This category of environment in the USA, it is unlikely that actual cost data will be forthcoming from hospitals in the near future. In charges was more than four times greater in ICU patients than in non-ICU patients, though as might be expected, addition, this analysis reflects only hospital charges associated with the primary hospitalization. Physician charges, there was a wide range of charges ($3416 to $69 897), consistent with the highly variable outcomes in BMT patients charges for pre-transplant work-up, acquisition of stem cells, and subsequent hospital admissions or continued outtransferred to the ICU.
This study is the first detailed analysis of hospital charges patient transfusion support are not included in this analysis.
